论文部分内容阅读
糖尿病专家担心近期发表的与史克 -比彻姆公司生产的口服抗糖尿病药罗格列酮 ( rosiglitazone,Avandia)有关的两份肝功能丧失的报告会导致患者中止许多必要的治疗。 1月份 Ann Intern Med杂志上报道 2名接受罗格列酮的患者发生肝功能衰竭和肝细胞损害 ,这两种情况是患者停药后
Diabetes experts are concerned that the recent report of two loss of liver function associated with the oral antidiabetic rosiglitazone (Avandia) produced by the Schneider-Becciam Company will cause the patient to discontinue many of the necessary treatments. Ann Intern Med in January reported two patients with rosiglitazone who developed liver failure and hepatocellular damage, both in patients who discontinued treatment